The findings underscore the critical role of CERK in regulating ferroptosis and suggest a potential therapeutic strategy for NSCLC with KRAS mutations by targeting CERK and modulating the AKT pathway (Vu et al., 2022). The gene discussed is AKT1; the disease is non-small cell lung carcinoma.